Diabetes prevention: A review of current literature

Advanced Studies in Medicine

Volumn 5, Issue 5, 2005, Pages 250-259

  Angelo, Jennifer B ^a   Huang, Jian ^a   Carden, Donna ^a,b  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; MEDROXYPROGESTERONE; METFORMIN; NIFEDIPINE; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; TETRAHYDROLIPSTATIN; TRANDOLAPRIL; TROGLITAZONE; VALSARTAN; VERAPAMIL;

CLINICAL TRIAL; DIET; DISEASE COURSE; HIGH RISK POPULATION; HUMAN; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; RISK FACTOR; WEIGHT REDUCTION;

EID: 19544389318     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
3. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002 JAMA. 2004;291:2847-2850.
4. United States Department of Health and Human Services, HHS, ADA warn Americans of "pre-diabetes," encourage people to take healthy steps to reduce risks, March 27, 2002. Available at: http://www.hhs.gov/news/press/ 2002pres/20020327\html. Accessed April 2, 2005.
5. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus In the United States JAMA. 2003;290:1884-1890.
6. King H, Aubert RE, Herman WH, Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431
7. Colditz GA, Willed WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus In women, Ann, Infern Med. 1995;122:481-486.
8. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-797.
9. Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women, Am J Epidemiol, 1990;132:501-513.
10. Kleinman JC, Donahue RP, Harris MI, et al. Mortality among diabetics in a national sample. Am J Epidemiol. 1988;128:389-401.
11. UK Prospective Diabetes Study Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in: Lancet 1999;354:602]. Lancet. 1998;352:837-853.
12. Hogan P, Dall T, Nikolov P, for the American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-932.
13. Turner RC, Cull CA, Fright V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49), UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
14. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemie control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
15. DeFronzo RA Lilly Lecture 1987: The triumverate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes. 1988;37:667-687.
16. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease, Diabetes Care. 1991;14:173-194.
17. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes, Endocr Rev. 2002;23:201-229.
18. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143:339-342.
19. Liu RH, Mizuta M, Kurose T, et al. Early events involved in the development of insulin resistance in Zucker fatty rat. Int J Obes Relat Metab Disord. 2002;26:31 8-326.
20. Chan DC, Watts GF, Sussekov AV, et al. Adipose tissue compartments and insulin resistance in overweight-obese Caucasian men. Diabetes Res Clin Pract. 2004;63:77-85.
21. Yamashita S, Nakamura T, Shimomura I, et al. Insulin resistance and body fat distribution. Diabetes Care. 1996;19:287-291.
22. Abate N, Garg A, Peshock RM, et al. Relationships of generalized and regional adiposity to insulin sensitivity in men, J Clin Invest. 1995;96:88-98.
23. Weyer C, Bagardus C, Pratley RE, Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes, 1999;48:2197-2203.
24. Poquot N, Scheen AJ, Dirlewanger M, et al. Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients. Obes Res, 2002;10:129-134.
25. Pratipanawatr T, Pratipanawatr W, Rosen C, et al. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab. 2002;282:E1360-E1368.
26. Eriksson J, Fransilla-Kallunki A, Ekstrand A, et al. Early metabolic defects In persons at increased risk for non-insulin-dependent diabetes mellitus, N Engl J Med. 1989;321:337-343.
27. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states: sequence of events leading to non-insulin-dependent diabetes mellitus, J Clin Invest. 1994;94:1714-1721.
28. Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of beto-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47:358-364.
29. Bastard J-P, Maachi M, van Nhieu JT, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro, J Clin Endocrinol Metab. 2002;87:2084-2089.
30. Ventre J, Doebber T, Wu M, et al. Targeted disruption of the tumor necrosis factor-a gene, Metabolic consequences in obese and nonobese mice. Diabetes. 1997;46:1526-1531.
31. Berg AH, Combs TP, Scherer PE. ACRPSO/adiponectin; an adipokine regulating glucose and lipid metabofism. Trends Endocrinol Metab. 2002;13:84-89,
32. Stppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.
33. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus, Ann NY Acad Sci. 2002;967:363-378.
34. Knowler WC, Barrert-Connor E, Fowler SE, et al, for the Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
35. Eriksson KF, Lingärde F, Prevention of type 2 (non-insulin- cependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study, Diabetologia. 1991;34:891-898.
36. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
37. Tuomilehto J, Lindstrodie;m J, Eriksson JG, et al. Prevention of type 2 diabefes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N Englj Med. 2001;344:1343-1350.
38. Van Dam RM, Rimm EB, Willett WC, et al. Dietary patterns and risk for type 2 diabetes mellitus in U.S, men. Ann Intern Med. 2002;136:201-209.
39. Eriksson KF, Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise. Diabetologia. 1998;41:1010-1016.
40. Hu FB, van Dam RM, Liu S, Diet and risk of Type II diabetes: the role of types of fat and carbohydrate. Diabetologia. 2001;44:805-817.
41. Porilio M, Rivellese AA, Ciardullo AV, et al. A high-monounsaturated-fat/ low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients. Metabolism. 1992;41:1373-1378.
42. Vessby B, Unsitupa M, Hermansen K, et al, for the KANWU Study. Substituting dietary saturated for monounsaturoted fat impairs insulin sensitivity in healthy men and women: The KANWU Study, Diabetologia. 2001;44:312-319.
43. Houtsmuller AJ, van Hal-Ferwerda J, Zahn KJ, et al. Favourable influences of linoleic acid on the progression of diabetic micro- and macroangiopathy, Nutr Metab. 1980;24(suppl 1):105-118.
44. Heine RJ, Mulder C, Popp-Snijders C, et al. Linoleic-acid-enriched diet: long term effects on serum lipoprotein and apolipoprotein, concentrations and insulin sensitivity in noninsulin-dependent diabetic patients, Am J Oin Nutr. 1989;49:448-456.
45. Chrlstiansen E, Schnider S, Palmvig B, et al. Intake of a diet high in trans monounsaturated fatly acids or saturated fatty acids: effects on postprandial insulinemia and glycemia in obese patients with NIDDM. Diabetes Care, 1997;20:881-887.
46. Rivellese A, Riccardi G, Giacco A, et al. Effect of dietary fibre on glucose control and serum lipoproteins in diabetic patients, Lancet. 1980;2:447-450.
47. Anderson JW, Gustafson NJ, Bryant CA, et al. Dietary fiber and diabetes; a comprehensive review and practical application. J Am Diet Assac. 1987;87:1189-1197.
48. Sjogren A, Floren CH, Nilsson A, Oral administration of magnesium hydroxide to subjects with insulin-dependent diabetes mellitus: effects on magnesium and potassium levels and on insulin requirements. Magnesium. 1988;7:117-122.
49. Lopez-Ridaura R, Willett WC, Rimm EB, et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Core. 2004;27:134-140.
50. Jiang R, Manson JE, Stampfer MJ, et al. Nut and peanut butter consumption and risk of type2 diabetes in women, JAMA. 2002;288:2554-2560.
51. Ivy JL, Zderic TW, Fogt DL. Prevention and treatment of noninsulin-dependent diabetes mellitus, Exerc Sport Sci Rev. 1999;27;1-35.
52. Helmrich SP, Ragland DR, Leung RW, et al. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Eng J Med. 1991;325:147-152,
53. Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women, Lancet. 1991;338:774-778.
54. Manson JE, Nathan DM, Krolewski AS, et al. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA. 1992;268:63-67.
55. Folsom AR, Kushi LH, Hong CP Physical activity and incident diabetes mellitus in postmenopausal women. Am J Public Health. 2000;90:134-138.
56. Kriska AM, Saremi A, Hanson RL, et al. Physical activity, obesity, and the incidence of type 2 diabetes in a high-risk population, Am J Epidemiol. 2003;158:669-675.
57. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1990;334:574-579.
58. Freemark M. Pharmacologie approaches to the prevention of type 2 diabetes in high risk pediatrie patients, J Clin Endocrinol Metab. 2003;88:3-13.
59. Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457-1461.
60. Lehtovirta M, Forsen B, Gullstrom M, et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med. 2001;18:578-583.
61. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003;26:977-980.
62. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care. 1997;20:1183-1197.
63. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year folbw-up study, lancet, 1992;340:925-929.
64. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787-794.
65. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51:2796-2803.
66. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701-710.
67. Kios SL, Peters RK. Xiang A, et al. Predicting future diabetes in Latino women with gestational diabetes: utility of early postpartum glucose tolerance testing. Diabetes, 1995;44:586-591.
68. Kramer D, Shapiro R, Adler A, et al. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats, Metabolism. 2001;50:1294-1300.
69. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094-2099.
70. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling, J Clin Invest. 1997;100:1863-1869.
71. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:56-59
72. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program [abstract]. Diabetes. 2003; 52(suppl l):A58-A59.
73. Chiasson JL, Gomis R, Hanefeld M, et al. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Depenaent Diabetes Mellitus. Diabetes Care. 1998;21:1720-1725.
74. Chiasson JL, Josse RG, Leiter LA, et al. The effect of acorbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Core, 1996;19:1191-1194.
75. Chiasson JL, Josse RG, Gomis R, et al. for the STOP-NIDDM Trial Research Group, Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial, Lancet. 2002;359:2072-2077.
76. World Health Organization, The World Health Report 1997 - Conquering Suffering, Enriching Humanity. Geneva, Switzerland: World Health Organization; 1997.
77. Simpson RW, Shaw JE, Zimmet PZ. The prevention of type 2 diabetes-lifestyle change or pharmacotherapy? A challenge for the 21st century. Diabetes Res Clin Pract. 2003;59:165-180.
78. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial [published correction appears in JAMA. 1999;281:1174]. JAMA. 1999;281:235-242.
79. Sjöström L, Rissonen A, Andersen T, et al. Randomised place-bo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients, Lancet. 1998:352:167-173.
80. Heymsfiefd SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160:1321-1326.
81. Torgerson JS, Hauptman J, Boldrin M, et al. XENical in the prevention of diabetes In obese subjects (XENDOS) study a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [published correction appears in Diabetes Care. 2004;27:856], Diabetes Care, 2004;27:155-161.
82. Long SD, O'Brien K, MacDonald KG Jr, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study, Diabetes Care. 1994;17:372-375.
83. Torgerson JS, Siöström L. The Swedish Obese Subjects (SOS) study-rationale and results. Int J Obes Relat Metab Disord. 2001;25(suppl 1):S2-S4.
84. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meto-analysis. JAMA. 2004;292:1724-1737.
85. Yusuf DP, Gerstein H, Hoogwerf B, et al, for the HOPE Study Investigators. Ramipril and the development of diabetes, JAMA, 2001;286:1882-1885.
86. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
87. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
88. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [published correction appears in Lancet. 2000;356:514], Lancet. 2000;356:366-372.
89. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al, for the INVEST Investigators, A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease, The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial, JAMA. 2003;290:2805-2816.
90. Devereux RB, Dahlöf B, Kjeldsen SE, et al, for the LIFE Study. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med. 2003;139:169-177.
91. Lithell H, Hansson L, Skoog I, et al, for the SCOPE Study Group, The Study on Cognition and Prognosis In the Elderly (SCOPE): principal results of a randomized double-blind intervention trial, J Hypertens. 2003;21:875-886.
92. Julius S, Kjeldsen SE, Weber M, et al, for the VALUE trial group. Outcomes In hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial, Lancet. 2004;363:2022-2031.
93. Pfeffer MA, Swedberg K, Granger CB, et al, for the CHARM Investigators and Committees. Effects or candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM Overall programme, Lancet. 2003;362:759-766.
94. Freeman DJ, Norrle J, Sattar N, et al. Pravastatin and the development of diabetes mellitus; evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study, Circulation. 2001;103:357-362.
95. Collins R, Armitage J, Parish S, et al, for the Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005-2016.
96. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial, Lancet. 2003;361:1149-1158.
97. Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197-2202.
98. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomised, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1-9.
99. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905-912.
100. Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular out-comes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy [published correction appears in Lancet. 2000;356:860]. Lancet. 2000;355:253-259.
101. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
102. Samuelsson O, Hedner T, Berglund G, et al. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens. 1994;8:257-263.
103. McFarlane SI, Muniyappa R, Francisco R. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metob. 2002;87:1451-1458.
104. American Diabetes Association, Standards of medical care in diabetes. Diabetes Care. 2004;27(suppl 1):S15-S35.
105. U.S. Preventive Services Task Force, Screening for obesity in adults: recommendations and rationale. Ann Intern Med. 2003;139:930-932
106. Lindstrom J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26:3230-3236.
107. Harris MI. Diabetes in America; epidemiology and scope of the problem, Diabetes Care. 1998;21(suppl 3):C11-C14.
108. Wing R, Venditti E, Jakicic J, et al. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care. 1998;21:350-359.